To target acute myeloid leukemia cells, where the upregulation of both CD117 and transferrin receptors has been documented, Zhu et al. developed a binary drug delivery system comprising nanoparticles loaded with daunorubicin (DN) and adorned with the CD117 aptamer (Apt) and nanoparticles loaded with luteolin (LUT) and decorated with transferrin (Tf). Here, KIT is linked to acute myeloid leukemia.